肺癌免疫治疗中的性别差异:平衡还是偏倚?
该社论评述Suazo-Zepeda等在Thorax发表的系统综述与Meta分析(55项随机对照试验、28550例患者),指出女性在免疫检查点抑制剂(ICI)研究中明显代表性不足(28.4%),ICI虽在両性均改善总生存(OS),但无进展生存(PFS)获益在男性显著更大,并提出该差异反映真实生物学差异还是试验设计与患者选择中的残余混杂这一重要问题。
要点
- 女性在ICI随机对照试验中明显代表性不足,仅占28.4%。
- ICI在両性均改善OS,但PFS获益在男性显著更大。
- 性别差异是生物学可信但尚未充分理解的疗效决定因素。
核心结论
- ICI在両性均改善OS,但PFS获益在男性显著更大,该差异究竟反映真实生物学差异还是试验设计与患者选择中的残余混杂尚不明确。
研究设计与样本
- 本文为社论,评述Suazo-Zepeda等发表的系统综述与Meta分析,该分析纳入55项随机对照试验、共28550例患者,评估ICI疗效的性别差异。
主要发现
- 女性在纳入研究中明显代表性不足,占28.4%。
- ICI在男女両性均改善OS。
- PFS获益在男性显著大于女性。
- 女性通常产生更强的固有和适应性免疫应答。
局限性
- 原文指出性别差异是生物学可信但尚未充分理解的疗效决定因素。
- 原文提出该差异究竟反映真实生物学差异还是试验设计与患者选择中的残余混杂尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The incorporation of immune checkpoint inhibitors (ICIs) has transformed the management of advanced non-small cell lung cancer, establishing immunotherapy as a cornerstone of treatment. However, the therapeutic benefit remains heterogeneous, and identifying factors that influence response is essential to advancing precision oncology. Among these factors, sex is a biologically plausible yet incompletely understood determinant. In this issue of Thorax , Suazo-Zepeda et al. present a comprehensive systematic review and meta-analysis of 55 randomized controlled trials, including 28 550 patients, that evaluate sex-based differences in ICI effectiveness. 1 Women were markedly under-represented (28.4%). Although ICIs improved overall survival (OS) in both sexes, the progression-free survival (PFS) benefit was significantly greater in men. These findings raise an important question: do they reflect true biological differences or residual confounding embedded in trial design and patient selection? Sex-based differences in immune function are well established. Women generally mount stronger innate and adaptive immune responses,...
引用
- Thorax:Sex differences in immunotherapy for lung cancer: balance or bias?
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。